MADRIGAL PHARMACEUTICALS, INC. short interest in 2026
In 2026, MADRIGAL PHARMACEUTICALS, INC.'s disclosed short interest ran from 16.99% of shares outstanding on 15 Jan 2026 to 9.76% on 15 Sep 2026, a change of -7.23 percentage points. The year's high was 17.54% on 30 Jan 2026 and its low 8.51% on 31 Jul 2026, averaging 14.47% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.47 days on 30 Apr 2026. Full history: MADRIGAL PHARMACEUTICALS, INC..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 16.99% (15 Jan 2026)
- End of year
- 9.76% (15 Sep 2026)
- Change
- -7.23 pp
- High
- 17.54% (30 Jan 2026)
- Low
- 8.51% (31 Jul 2026)
- Average
- 14.47%
- Highest days to cover
- 16.47 (30 Apr 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 16.99% | 9.77 | |
| 30 Jan 2026 | 17.54% | 12.69 | |
| 13 Feb 2026 | 15.78% | 11.08 | |
| 27 Feb 2026 | 16.31% | 8.16 | 10-K filed, results (8-K) |
| 13 Mar 2026 | 17.13% | 13.93 | |
| 31 Mar 2026 | 17.04% | 9.12 | |
| 15 Apr 2026 | 17.49% | 12.69 | |
| 30 Apr 2026 | 16.80% | 16.47 | |
| 15 May 2026 | 16.90% | 12.33 | 10-Q filed, results (8-K) |
| 29 May 2026 | 16.58% | 14.08 | |
| 15 Jun 2026 | 16.40% | 14.32 | |
| 30 Jun 2026 | 15.30% | 6.20 | |
| 15 Jul 2026 | 8.95% | 6.94 | |
| 31 Jul 2026 | 8.51% | 4.84 | 10-Q filed, results (8-K) |
| 14 Aug 2026 | 8.77% | 6.05 | |
| 31 Aug 2026 | 9.70% | 9.46 | |
| 15 Sep 2026 | 9.76% | 11.42 |
See also: MADRIGAL PHARMACEUTICALS, INC.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.